Clinical manifestations, molecular characteristics, antimicrobial susceptibility patterns and contributions of target gene mutation to fluoroquinolone resistance in Elizabethkingia anophelis

The Journal of Antimicrobial Chemotherapy
Jiun-Nong LinHsi-Hsun Lin

Abstract

Elizabethkingia anophelis has recently emerged as a cause of life-threatening infections in humans. We aimed to investigate the clinical and molecular characteristics of E. anophelis. A clinical microbiology laboratory database was searched to identify patients with Elizabethkingia infections between 2005 and 2016. Isolates were re-identified and their species were confirmed using 16S rRNA gene sequencing. Patients with E. anophelis infections were included in this study. Clinical information, antimicrobial susceptibility and mutations in DNA gyrase and topoisomerase IV were analysed. A total of 67 patients were identified to have E. anophelis infections, including 47 men and 20 women, with a median age of 61 years. Comorbidity was identified in 85.1% of the patients. Among the 67 E. anophelis isolates, 40 (59.7%) were isolated from blood. The case fatality rate was 28.4%. Inappropriate empirical antimicrobial therapy was an independent risk factor for mortality (adjusted OR = 10.01; 95% CI = 1.20-83.76; P = 0.034). The isolates were 'not susceptible' to multiple antibiotics. All the isolates were susceptible to minocycline. Susceptibilities to ciprofloxacin and levofloxacin were 4.5% and 58.2%, respectively. Mutations in DNA g...Continue Reading

References

Jun 9, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·George A Jacoby
Jul 13, 2007·Journal of Clinical Microbiology·J Michael Janda, Sharon L Abbott
Nov 6, 2008·International Journal of Systematic and Evolutionary Microbiology·Elionora Hantsis-ZacharovMalka Halpern
Jul 7, 2009·Scandinavian Journal of Infectious Diseases·Yi-Tsung LinCheng-Yi Liu
Dec 21, 2010·International Journal of Systematic and Evolutionary Microbiology·Peter KämpferIngrid Faye
Apr 5, 2011·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·M-S HsuP-R Hsueh
Jun 6, 2012·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Isabel S HenriquesAntónio Correia
May 18, 2013·Pediatrics International : Official Journal of the Japan Pediatric Society·Paulo Sergio Lucas da Silva, Graziella Hanna Pereira
Sep 10, 2013·Lancet·Jeanette TeoLiang Yang
Dec 10, 2016·MMWR. Morbidity and Mortality Weekly Report·Livia NavonAinsley Nicholson

❮ Previous
Next ❯

Citations

Aug 31, 2019·Microorganisms·Jiun-Nong LinYi-Han Huang
Jul 29, 2019·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·Tein-Yao ChangJun-Ren Sun
Mar 4, 2021·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Paige M K LarkinPaul Allyn
Mar 12, 2021·FEMS Microbiology Letters·Chen YangDingxia Shen

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

© 2022 Meta ULC. All rights reserved